The Case for TNIK + GLP-1 Combination Therapy
How combining TNIK inhibitors with GLP-1 agonists could create the first obesity treatment that preserves muscle mass while maximizing fat loss
April 2026 | MolForge Research
20–40%
Lean mass lost with GLP-1 alone
$100B+
Obesity drug market (2030F)
0
Combination trials (TNIK + GLP-1)
01
GLP-1's Muscle Problem Is Getting Worse
As GLP-1 agonists deliver higher weight loss (16–21%), the absolute amount of lean muscle lost increases proportionally. Patients on semaglutide lose ~39% of total weight as lean mass. With chronic use, this accelerates sarcopenia, reduces metabolic rate, and creates a “weight cycling” trap: patients regain fat faster than muscle after discontinuation.
The Cycle
GLP-1 → Weight loss (fat + muscle) → Lower metabolic rate → Drug discontinuation → Rapid fat regain (muscle slower) → Net worse body composition → Restart GLP-1 at higher dose
02
The Combination Thesis: TNIK + GLP-1
TNIK inhibition and GLP-1 agonism operate through entirely orthogonal mechanisms. GLP-1 suppresses appetite centrally. TNIK controls peripheral lipogenesis. Together, they could deliver superior fat-specific weight loss while preserving the muscle mass that GLP-1 alone destroys.
| Mechanism | GLP-1 Alone | TNIK Alone | GLP-1 + TNIK |
|---|---|---|---|
| Appetite suppression | Strong | None | Strong |
| De novo lipogenesis block | None | Strong | Strong |
| Muscle preservation | Poor (20–40% lean loss) | Preserved (KO mice) | Expected: preserved |
| Insulin sensitivity | Moderate | Enhanced | Additive |
| NAFLD protection | Partial | Strong | Additive |
| Energy expenditure | Reduced | Increased | Net positive |
03
Mechanistic Rationale
GLP-1 Pathway
- Central appetite suppression (hypothalamus)
- Delayed gastric emptying
- Increased insulin secretion
- Non-selective weight loss (fat + muscle)
TNIK Pathway
- Blocks de novo lipogenesis (liver, adipose)
- Redirects glucose to oxidation, not fat storage
- Increases physical activity (KO mouse phenotype)
- Preserves lean mass independently
“GLP-1 tells the brain to eat less. TNIK tells the body to stop making fat from what it does eat. The combination attacks obesity from both sides of the energy equation.”
04
Why No One Is Doing This Yet
- TNIK was validated as a drug target only recently (rentosertib Phase IIa, June 2025)
- The obesity/metabolic TNIK data (Pham et al. 2023) has not been pursued clinically
- Insilico Medicine’s TNIK program is locked into IPF via the Eli Lilly deal
- No other company has a clinical-stage TNIK inhibitor with obesity-relevant selectivity
- Big pharma GLP-1 franchises (Novo, Lilly) have no incentive to add a competing mechanism
This creates a narrow window for a focused player to develop obesity-optimized TNIK inhibitors and position them as combination partners for the existing GLP-1 franchise holders.
05
MolForge's Position
33,755
TNIK compounds ADMET-validated
<0.21
Tanimoto vs rentosertib (FTO clear)
4
Leads in CRO validation
2
Indications: CRC (lead) + Obesity
MolForge's TNIK compound library is optimized for selectivity, oral bioavailability, and safety — the exact profile needed for a chronic obesity combination therapy. Our compounds are structurally differentiated from rentosertib (Tanimoto <0.21), providing clear freedom-to-operate.
06
The Business Case
| Scenario | Market Access | Est. Peak Revenue |
|---|---|---|
| TNIK monotherapy (CRC) | Oncology niche | $500M–$2B |
| TNIK monotherapy (obesity) | Broad metabolic | $5B–$15B |
| TNIK + GLP-1 combination | Standard of care addon | $10B–$30B+ |
The combination play transforms TNIK from a niche oncology asset into a potential standard-of-care component for the world's largest drug market. For GLP-1 franchise holders, adding a muscle-preserving mechanism is not optional — it's the next competitive battleground.
Interested in TNIK + GLP-1 combination licensing?
MolForge is seeking partners to co-develop TNIK inhibitors optimized for combination with GLP-1 agonists.
Contact UsReferences
- [1]Pham, D.D. et al. "TNIK knockout prevents diet-induced obesity by enhancing energy expenditure." Science Advances, 2023.
- [2]Wilding, J.P.H. et al. "Once-weekly semaglutide in adults with overweight or obesity." NEJM, 2021.
- [3]Jastreboff, A.M. et al. "Tirzepatide once weekly for the treatment of obesity." NEJM, 2022.
- [4]Heymsfield, S.B. et al. "Mechanisms, pathophysiology, and management of obesity." NEJM, 2017.
- [5]Levin, J. et al. "Rentosertib Phase 2a results in idiopathic pulmonary fibrosis." Nature Medicine, 2025.
- [6]Pun, F.W. et al. "AI-powered therapeutic target discovery." Trends in Pharmacological Sciences, 2024.
- [7]Eli Lilly and Insilico Medicine $2.75B licensing agreement. Press release, March 2026.